We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

By LabMedica International staff writers
Posted on 07 Aug 2025

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory, and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar.

"Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Mdxhealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate to their portfolio accelerates their leadership in this market."


Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

"Following this transaction, Bio-Techne will strengthen its foundation as a developer of innovative, high-value, high-margin products, tools, and reagents for the life science research and clinical diagnostics markets. This repositioning of the portfolio enables Bio-Techne to direct additional investments to further strengthen this foundation, while creating an immediate uplift to our sector-leading operating margin profile," added Kelderman.

"ExoDx Prostate is a strong strategic fit with our rapidly growing urology and prostate cancer diagnostic business," said Michael McGarrity, Chief Executive Officer of Mdxhealth. "The ExoDx Prostate test equips men with information to make better decisions and avoid unnecessary and potentially dangerous prostate biopsies. Bio-Techne has done a tremendous job delivering this necessary information to patients and growing the base of physicians leveraging this tool. We are looking forward to building on this success."

Related Links:
Bio-Techne Corporation
Exosome Diagnostics Inc.
Mdxhealth SA 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Rapid Test Reader
DIA5000
New
Rapid Molecular Testing Device
FlashDetect Flash10

Latest Industry News

Siemens Healthineers and Carna Health Partner to Advance Kidney Care Innovation
07 Aug 2025  |   Industry

Vircell Launches New Website for Molecular Control Products
07 Aug 2025  |   Industry

Tempus AI Acquires Digital Pathology Company Paige
07 Aug 2025  |   Industry